ClinicalTrials.gg
RecruitingNCT05823636Updated Sep 26, 2024

The Clinical Course and Factors for the Progression of Uninvestigated Dyspepsia to Functional Dyspepsia

An observational study in Dyspepsia, sponsored by Air Force Military Medical University, China. Recruiting at 1 site in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-09-26.

Sponsored by Air Force Military Medical University, China · Observational

From the registry’s dates

  • Primary completion was expected by Jun 2025, 1 year 4 months ago, but the record still lists the study as recruiting.
  • Started Jan 2023; still recruiting 3 years 10 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
220
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 58 studies in Dyspepsia with a site in China — 9 open to participants now, 10 under way, none of them phase 3. Dyspepsia · China.

Planned enrollment
9th of 12
220 · median 450
Started
2023
with 2 others
Observational
12 of 58
3 open now
Registered
46th of 58
by date
Lead sponsor
8 of 58
Air Force Military Medical University, China

Among the 58 studies in Dyspepsia with a site in China, this one is the 9th largest by planned enrollment of the 12 observational ones that give a count, is one of 3 that started in 2023, is one of 12 observational ones, and was the 46th registered.

Dyspepsia

372 studies on the registry are indexed under Dyspepsia; 66 are open to participants now.

Browse Dyspepsia studies →

Open to participants now

9 of the 58 studies in Dyspepsia with a site in China are open now. Recruiting first, the newest first:

3 more — sign in →

All 9 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 46 Dyspepsia studies recruiting now, 16 (35%) set no upper age limit and 23 (50%) stop at 75 or younger; 2 take children under 18; 8 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 58 studies in Dyspepsia with a site in China, or all of them as a file.
02

Study summary

Dyspepsia is one of the most common gastrointestinal diseases. This disease was defined as predominant epigastric pain lasting for at least 1 month, which can be accompanied with other symptoms, such as epigastric fullness, and early satiety. Despite dyspepsia symptoms lasting for ≥1 month represented clinical problem, a longer duration of 6 months or more after first-onset symptom was required for the diagnosis of functional dyspepsia based on ROME IV criteria. It was unclear about the natural procession of first-onset dyspepsia to functional dyspepsia assessed by Rome IV or Asia criteria and possible factors associated with this progression.

03

Conditions studied

  • Dyspepsia

Browse trials for

Keywords

  • Functional Dyspepsia
  • uninvestigated dyspepsia
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Probability sample

Study population

Patients aged ≥ 18 years old who had first-onset dyspepsia with one or more symptoms of epigastric pain, epigastric burning, postprandial fullness, early satiation and that has lasted for more than 1 month to 3 months.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients aged ≥ 18 years old who had first-onset dyspepsia with one or more symptoms of epigastric pain, epigastric burning, postprandial fullness, early satiation and that has lasted for more than 1 month to 3 months.

Exclusion criteria

Exclusion Criteria:

  1. Patients with local or systemic diseases which may cause dyspeptic symptoms:

    Known active peptic ulcer, cholecystitis, gallstone, gastrointestinal obstruction, gastroparesis, and etc.

  2. Known acute or chronic injury of liver or kidney
  3. Obvious hematological abnormality, or endocrine and metabolic diseases
  4. Known ; Obvious cardiovascular or cerebrovascular diseases (such as coronary heart disease, arrhythmia, cerebral infarction and etc.
  5. Other conditions which may be associated with dyspeptic symptoms (such as NSAIDs associated dyspepsia)
  6. organ failure defined by Marshall standard or severe psychiatric illnesses
  7. pregnancy or lactation
  8. unable to provide consent
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
220 participants (estimated)
Patient registry
No

Groups and cohorts

  • uninvestigated dyspepsia

    Patients aged ≥ 18 years old who had first-onset dyspepsia with one or more symptoms of epigastric pain, epigastric burning, postprandial fullness, early satiation and that has lasted for more than 1 month to 3 months.

06

What researchers measure

Primary outcomes

  1. Functional dyspepsia defined by ROME IV criteria

    Met the following criteria: by one or more of the following symptoms: postprandial fullness, early satiation, epigastric pain, and epigastric burning that are unexplained after a routine clinical evaluation, Criteria fulfilled for the last 3 months with symptom onset at least 6 months before diagnosis.

    Time frame: 6 months

Secondary outcomes

  1. Functional dyspepsia defined by Asia criteria:

    Met the following criteria: by one or more of the following symptoms: postprandial fullness, early satiation, epigastric pain, and epigastric burning that are unexplained after a routine clinical evaluation, the symptoms duration≧3 months.

    Time frame: 3 month

  2. Global Overall Symptom score (GOSS)

    The GOSS consists of 10 cardinal items (epigastric pain, epigastric discomfort, Heartburn, acid regurgitation, upper abdominal bloating, belching, nausea, early satiety, postprandial fullness, other epigastric symptoms(eg. epigastric burning). Each item can be scored from 1 (no) to 7 (worst).

    Time frame: 1month, 3 months, 6 months

  3. Number of participants subclassified into different subtypes of functional dyspepsia defined by ROME IV criteria

    Functional dyspepsia was classified into three subgroups:(1) Postprandial Distress Syndrome, defined as Bothersome postprandial fullness or/and Bothersome early satiation. (2) Bothersome epigastric pain AND/OR Bothersome epigastric burning. (3) mixed syndrome, defined when postprandial distress syndrome and epigastric pain syndrome presented simultaneously.

    Time frame: 6 months

  4. Short Form of Nepean Dyspepsia Index (SF-NDI)

    The SF-NDI consists of 10 questions regarding the effects of dyspepsia symptoms ("stomach problems") on different aspects of life (tension, interference with daily activities, eating/drinking, knowledge/control, and work/study). Each response can be from 1 (not at all affected) to 5 (extremely affected), or 0 (N/A), for a total summed score out of 50.

    Time frame: 1month, 3 months, 6 months

  5. Hospital anxiety and depression scale

    Anxiety and depression of patients are assessed by using Hospital Anxiety and Depression Scale.It contains 14 items (7 anxiety and 7 depression), which assess symptoms experienced during the past week on a 0-3 scale. A subscore of \> 8 for depression or anxiety would indicate a clinical case.

    Time frame: 1month, 3 months, 6 months

  6. Quality of Life scores

    Quality of Life scores assessed by Patient-reported outcomes measurement information system (PROMIS) Global-10 questionnaire. PROMIS Global-10 is a newly validated 10-question survey used to assess health care-related quality of life measures for the general population. It's a 10-item patient-reported questionnaire in which the response options are presented as 5-point (as well as a single 11-point) rating scales. These scores are then standardized to the general population, using the "T-Score". The average "T-Score" for the United States population is 50 points, with a standard deviation of 10 points. Higher scores indicate a healthier patient and a better quality of life.

    Time frame: 1month, 3 months, 6 months

  7. Self-reported severity of symptoms by patients

    Patients rated the severity of dyspepsia as mild, moderate, and severe by themselves

    Time frame: 1 day

  8. Number of participants with other functional gastrointestinal diseases defined by ROME IV criteria

    Recurrent functional dysphagia, reflux hypersensitivity, irritable bowel syndrome, etc.

    Time frame: 1 day

07

Study locations

1 of 1 sites recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jan 2023 (actual). Primary completion is estimated for Jun 2025, 29 months after the start.

Of 22 observational studies under Dyspepsia, half reached primary completion within 23 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 47. This study's planned 29 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 26, 2023
First posted
Apr 21, 2023
StartActual
Jan 1, 2023
Primary completionEst.
Jun 30, 2025
CompletionEst.
Dec 31, 2025
Last update
Sep 26, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 26, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT05823636
Responsible party
Yanglin Pan (professor, Air Force Military Medical University, China) — Principal investigator
First posted
Apr 21, 2023
Start date
Jan 1, 2023
Primary completion
Jun 30, 2025 (estimated)
Completion
Dec 31, 2025 (estimated)
Last update
Sep 26, 2024

Study contacts

Yanglin Pan, MD
Contact
yanglinpan@hotmail.com
13991811225

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion